NEO: NeoGenomics Laboratories Average Forecast Price
The current market quotes on GURU.Markets visualized below confirm the resilience of NeoGenomics, Inc. (NEO) cash flows, which are based on the demand for oncology diagnostics. The indicator stands at 23.32. The business relies on a network of modern American laboratories, where strict adherence to sterility guarantees the accuracy of analyses. Currently, NeoGenomics, Inc. (NEO) is focusing on organic growth and updating its test menu, deliberately eschewing mergers in favor of partnerships with pharma behemoths.
Analytical breakdowns for NeoGenomics Laboratories (NEO)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio NeoGenomics, Inc.|NEO - Long-Term Debt to Capital|Current Liabilities to Capital NeoGenomics Corp|NEO - Company Debts|Debt to Book Value NeoGenomics Laboratories|NEO - Company Long-Term Debts|Short-Term Debt Volume NeoGenomics|Interim Coverage Ratio neogenomics.com
- earnings and multiples data:
NEO - Net Income|Future Net Profit NeoGenomics, Inc.|NEO - Price to Earnings Ratio|Future Price to Earnings Multiple NeoGenomics Inc|NEO - Price/Earnings to Growth Multiple|Company Value to EBITDA NeoGenomics Laboratories|NEO - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months NeoGenomics|NEO - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months neogenomics.com|NEO - Earnings per share growth in current year|Expected net earnings per share growth next year NeoGenomics, Inc.
Fundamental company analysis:NEO (neogenomics.com)
This metric aggregates investment bank forecasts, neutralizing the time gaps between quarterly reports. It determines the fundamental value potential of the asset via a weighted average target price. For NeoGenomics, Inc. (NEO), a steady stream of orders from clinics confirms the stability of this calculation. The current average target price for the stock stands at 23.32. The dynamics of this indicator allow investors to promptly assess marginal risks and the probability of a correction.
Competing companies
linde.com - Broker Consensus Forecast|Analyst Consensus Forecast APD (Air Products and Chemicals)|DuPont de Nemours (DD) - Average Forecast Price|IP - Price Target Chart|Average Forecast Price PPG Industries, Inc.|DOW: Analyst Consensus Forecast|Consensus Target lyondellbasell.com|IFF (International Flavors & Fragrances Inc) - Analyst Consensus Forecast|RPM: Fair Value Consensus|Analyst Consensus Forecast ENTG|SUZ - Average Forecast Price|Price Target Chart Westlake Corporation WLK|ALB - Consensus Target|ICL Group - Analyst Consensus Forecast|Analyst Median Target NewMarket Corp NEU|Eastman Chemical Corp (EMN) - Price Target Chart|AXTA - Analyst Median Target|Consensus Target ESI|SQM (sqm.com) - Analyst Forecast Prices|Price Target Chart Celanese (CE)|SXT (Sensient Technologies Corporation) - Fair Value Consensus|Cabot Microelectronics - Consensus Target|Hawkins Corp (HWKN) - Average Forecast Price|AVNT - Price Target Chart|FUL (hbfuller.com) - Broker Consensus Forecast|MEOH: Analyst Consensus Forecast|Average Forecast Price WD-40 Co. (WDFC)|Price Target Chart Chemours Corp|Average Forecast Price Quaker Chemical Corp. KWR|Analyst Consensus Forecast PCT|ashland.com (ASH) - Analyst Target Range|Analyst Consensus Forecast NGVT (Ingevity)|Innospec Inc (IOSP) - Average Forecast Price|MTX - Price Target Chart|DQ (Daqo Solar) - Broker Consensus Forecast|Sylvamo Corporation (SLVM) - Price Target Chart|Average Forecast Price huntsman.com (HUN)|Price Target Chart Albany International Corp.|Consensus Target Calumet Specialty Products Partners, L.P. (CLMT)|Analyst Consensus Forecast ROG|Analyst Median Target Stepan Chemical|Analyst Consensus Forecast ECVT (Ecovyst Inc.)|REX - Consensus Target|ASPI - Price Target Chart|Analyst Median Target Tronox Holdings TROX|GSM (Ferroglobe Corp) - Consensus Target|Westlake Partners - Fair Value Consensus|CMP (Compass Minerals) - Analyst Consensus Forecast|kronostio2.com (KRO) - Analyst Median Target|Price Target Chart Mativ (MATV)|LSB Industries Inc - Broker Consensus Forecast|Analyst Consensus Forecast BAK (Braskem Group)|KOP - Consensus Target|ASIX: Consensus Target|Analyst Median Target orioncarbons.com OEC|rayonieram.com (RYAM) - Price Target Chart|Broker Consensus Forecast ADUR|MAGN (Magnera Inc.) - Analyst Consensus Forecast|Average Forecast Price Clearwater Paper Corp. CLW|Price Target Chart Tredegar Corporation (TG)|CMT - Average Forecast Price|Analyst Consensus Forecast FF (FutureFuel)|FSI - Consensus Target|Pacific Ethanol - Analyst Consensus Forecast|Fair Value Consensus FEAM (5E Advanced Materials)|TSE: Analyst Consensus Forecast|Average Forecast Price Origin Materials (ORGN)|Price Target Chart Northern Technologies International|Consensus Target LanzaTech Global (LNZA)|Analyst Consensus Forecast YMAT|Analyst Median Target newerahelium.com|Price Target Chart Bolt Projects Holdings BSLK|Analyst Median Target BioNexus Gene Lab Corp (BGLC)|GURE: Consensus Target|CN Energy Group. Inc. - Analyst Forecast Prices|arcadiumlithium.com (ALTM) - Price Target Chart|Danimer Scientific, Inc - Fair Value Consensus|Consensus Target GLT|Average Forecast Price Graphex GRFX|Price Target Chart U.S. Silica (SLCA)|Invizyne Technologies Inc - Broker Consensus Forecast
